What to Know about Sequel Med Tech's twiist AID System, with Alan Lotvin, MD

The diabetes community welcomed an additional tool to the armamentarium with the US Food and Drug Administration’s clearance of the twiist automated insulin delivery (AID) system on March 18, 2024. Cleared for use in patients aged 6 years and older with type 1 diabetes, the twiist, which is marketed by Sequel Med Tech, is billed as the first drug delivery system that directly measures volume and flow of inulin delivered with every micro-dose.In this episode, Alan Lotvin, MD, co-founder and CEO of Sequel Med Tech, offers hosts a deep dive into the latest AID to receive approval, including the pump’s patient-centric design, why they chose to leverage the Tidepool Loop algorithm, plans for device launch, and more.Chapters 00:00 - Start01:00 - Lotvin Introduction03:25 - Differences from Current AIDs08:15 - Compatible CGMs10:25 - Plans for Launch12:05 - Design Discussion16:50 - iPhone vs Android Compatibility19:50 - Clinical Trials22:20 - Tidepool Loop Algorithm27:45 - Accuracy of Current Pumps